Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity

Eluxadoline (ELD), a recently approved drug, exhibits potential therapeutic effects in the management and treatment of IBS-D. However, its applications have been limited due to poor aqueous solubility, leading to a low dissolution rate and oral bioavailability. The current study’s goals are to prepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwer, Md. Khalid, Ahmed, Mohammed Muqtader, Aldawsari, Mohammed F., Iqbal, Muzaffar, Soliman, Gamal A., Aljuffali, Ibrahim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223546/
https://www.ncbi.nlm.nih.gov/pubmed/37242700
http://dx.doi.org/10.3390/pharmaceutics15051460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223546/
https://www.ncbi.nlm.nih.gov/pubmed/37242700
http://dx.doi.org/10.3390/pharmaceutics15051460

Ejemplares similares